肌萎缩性脊髓侧索硬化症早期血浆中可溶性 RAGE、AGEs 和 AOPPs 的水平:初步研究。

Q3 Medicine Polimery w medycynie Pub Date : 2023-07-01 DOI:10.17219/pim/175544
Judyta Juranek, Adam Osowski, Joanna Wojtkiewicz, Marta Banach
{"title":"肌萎缩性脊髓侧索硬化症早期血浆中可溶性 RAGE、AGEs 和 AOPPs 的水平:初步研究。","authors":"Judyta Juranek, Adam Osowski, Joanna Wojtkiewicz, Marta Banach","doi":"10.17219/pim/175544","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder with largely unknown pathogenesis and no effective cure. It is believed that several, not mutually exclusive mechanisms contribute to the pathogenesis and progression of this disease, including, among others, elevated oxidative stress, excitotoxicity, increased neuroinflammation, and protein aggregation. Receptor for advanced glycation end products (RAGE) is a part of immunoglobulin superfamily; it is believed to participate in ALS pathogenesis.</p><p><strong>Objectives: </strong>Our previous studies on ALS demonstrated that RAGE is likely one of the key players in ALS, acting on its own and in tandem with its oxidative stress and pro-inflammatory ligands, such as advanced glycation end products (AGEs) or advanced oxidation protein products (AOPPs). In this study, based on our previous results, we aimed to establish blood levels of soluble RAGE, AGE and AOPP in ALS patients.</p><p><strong>Material and methods: </strong>Forty-six coded and anonymized surplus plasma samples from ALS patients and non-neurological control were used in the study. The plasma levels of RAGE, AGE and AOPP were measured using enzyme-linked immunosorbent assay (ELISA) commercially available kits. Statistical evaluation of data was performed using one-way non-parametric analysis of variance (ANOVA) with Kruskal-Wallis post hoc test.</p><p><strong>Results: </strong>Our results revealed a decline in soluble RAGE level, concurrent with an increase in the levels of AGEs and AOPPs in blood samples from ALS patients, signifying a loss of neuroprotective form of RAGE and a simultaneous increase in AGE and AOPP production and uptake at the early stage of the disease.</p><p><strong>Conclusions: </strong>The results obtained from our study indicate that further longitudinal study of RAGE, AGE and AOPP levels would be beneficial, outlining the dynamics between RAGE and its ligand levels as the disease progresses, and making them valuable diagnostic tools and potential therapeutic targets.</p>","PeriodicalId":20355,"journal":{"name":"Polimery w medycynie","volume":" ","pages":"105-110"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Plasma levels of soluble RAGE, AGEs and AOPPs at the early stage of amyotrophic lateral sclerosis: A preliminary study.\",\"authors\":\"Judyta Juranek, Adam Osowski, Joanna Wojtkiewicz, Marta Banach\",\"doi\":\"10.17219/pim/175544\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder with largely unknown pathogenesis and no effective cure. It is believed that several, not mutually exclusive mechanisms contribute to the pathogenesis and progression of this disease, including, among others, elevated oxidative stress, excitotoxicity, increased neuroinflammation, and protein aggregation. Receptor for advanced glycation end products (RAGE) is a part of immunoglobulin superfamily; it is believed to participate in ALS pathogenesis.</p><p><strong>Objectives: </strong>Our previous studies on ALS demonstrated that RAGE is likely one of the key players in ALS, acting on its own and in tandem with its oxidative stress and pro-inflammatory ligands, such as advanced glycation end products (AGEs) or advanced oxidation protein products (AOPPs). In this study, based on our previous results, we aimed to establish blood levels of soluble RAGE, AGE and AOPP in ALS patients.</p><p><strong>Material and methods: </strong>Forty-six coded and anonymized surplus plasma samples from ALS patients and non-neurological control were used in the study. The plasma levels of RAGE, AGE and AOPP were measured using enzyme-linked immunosorbent assay (ELISA) commercially available kits. Statistical evaluation of data was performed using one-way non-parametric analysis of variance (ANOVA) with Kruskal-Wallis post hoc test.</p><p><strong>Results: </strong>Our results revealed a decline in soluble RAGE level, concurrent with an increase in the levels of AGEs and AOPPs in blood samples from ALS patients, signifying a loss of neuroprotective form of RAGE and a simultaneous increase in AGE and AOPP production and uptake at the early stage of the disease.</p><p><strong>Conclusions: </strong>The results obtained from our study indicate that further longitudinal study of RAGE, AGE and AOPP levels would be beneficial, outlining the dynamics between RAGE and its ligand levels as the disease progresses, and making them valuable diagnostic tools and potential therapeutic targets.</p>\",\"PeriodicalId\":20355,\"journal\":{\"name\":\"Polimery w medycynie\",\"volume\":\" \",\"pages\":\"105-110\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Polimery w medycynie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17219/pim/175544\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Polimery w medycynie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17219/pim/175544","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景:肌萎缩性脊髓侧索硬化症(ALS)是一种破坏性神经退行性疾病,其发病机制尚不清楚,也没有有效的治疗方法。据认为,有几种并不相互排斥的机制促成了这种疾病的发病和进展,其中包括氧化应激升高、兴奋毒性、神经炎症加重和蛋白质聚集等。高级糖化终产物受体(RAGE)是免疫球蛋白超家族的一部分,据信它参与了 ALS 的发病机制:我们以前对 ALS 的研究表明,RAGE 很可能是 ALS 的关键参与者之一,它既能单独发挥作用,也能与其氧化应激和促炎配体(如高级糖化终产物(AGEs)或高级氧化蛋白产物(AOPPs))共同发挥作用。在本研究中,我们在之前研究成果的基础上,旨在确定 ALS 患者血液中可溶性 RAGE、AGE 和 AOPP 的水平:研究使用了 46 份编码和匿名的 ALS 患者和非神经系统对照的剩余血浆样本。使用市售的酶联免疫吸附试验(ELISA)试剂盒测定血浆中 RAGE、AGE 和 AOPP 的水平。数据的统计评估采用单向非参数方差分析(ANOVA)和 Kruskal-Wallis 事后检验:结果:我们的研究结果表明,在 ALS 患者的血液样本中,可溶性 RAGE 水平下降的同时,AGEs 和 AOPPs 水平上升,这表明在疾病的早期阶段,RAGE 的神经保护形式丧失,而 AGE 和 AOPP 的产生和吸收同时增加:我们的研究结果表明,进一步对 RAGE、AGE 和 AOPP 水平进行纵向研究将是有益的,可以勾勒出随着疾病的进展,RAGE 及其配体水平之间的动态变化,使其成为有价值的诊断工具和潜在的治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Plasma levels of soluble RAGE, AGEs and AOPPs at the early stage of amyotrophic lateral sclerosis: A preliminary study.

Background: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder with largely unknown pathogenesis and no effective cure. It is believed that several, not mutually exclusive mechanisms contribute to the pathogenesis and progression of this disease, including, among others, elevated oxidative stress, excitotoxicity, increased neuroinflammation, and protein aggregation. Receptor for advanced glycation end products (RAGE) is a part of immunoglobulin superfamily; it is believed to participate in ALS pathogenesis.

Objectives: Our previous studies on ALS demonstrated that RAGE is likely one of the key players in ALS, acting on its own and in tandem with its oxidative stress and pro-inflammatory ligands, such as advanced glycation end products (AGEs) or advanced oxidation protein products (AOPPs). In this study, based on our previous results, we aimed to establish blood levels of soluble RAGE, AGE and AOPP in ALS patients.

Material and methods: Forty-six coded and anonymized surplus plasma samples from ALS patients and non-neurological control were used in the study. The plasma levels of RAGE, AGE and AOPP were measured using enzyme-linked immunosorbent assay (ELISA) commercially available kits. Statistical evaluation of data was performed using one-way non-parametric analysis of variance (ANOVA) with Kruskal-Wallis post hoc test.

Results: Our results revealed a decline in soluble RAGE level, concurrent with an increase in the levels of AGEs and AOPPs in blood samples from ALS patients, signifying a loss of neuroprotective form of RAGE and a simultaneous increase in AGE and AOPP production and uptake at the early stage of the disease.

Conclusions: The results obtained from our study indicate that further longitudinal study of RAGE, AGE and AOPP levels would be beneficial, outlining the dynamics between RAGE and its ligand levels as the disease progresses, and making them valuable diagnostic tools and potential therapeutic targets.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Polimery w medycynie
Polimery w medycynie Medicine-Medicine (all)
CiteScore
3.30
自引率
0.00%
发文量
9
审稿时长
53 weeks
期刊最新文献
Efficacy of sulforaphane in skin cancer animal models: A systematic review. Design of experiments and artificial neural networks as useful tools in the optimization of analytical procedure. High-filler content electrospun fibers from biodegradable polymers and hydroxyapatite: Toward improved scaffolds for tissue engineering. Interaction of meloxicam derivatives with phosphatidylcholine bilayers: A calorimetric study. Rheological properties of pharmaceutical substrates produced with Celugel.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1